The Business Research Company has released a report on the market for biosimilars referencing Roche’s (ROG: SIX) blockbuster cancer drug Rituxan/MabThera (rituximab).
North America accounted for 48% of the global market for these copycat biologics, according to the report, making it the most lucrative region, followed by Western Europe and Eastern Europe.
Looking ahead, the fastest-growing regions in the rituximab biosimilar market will be South America and Asia Pacific, where growth will be at compound annual growth rates (CAGRs) of 36.7% and 29.2%, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze